Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Ulcerative Colitis

The Role of Beta-1,3/1,6-D-Glucan From Mycelium Extract of Indonesian Ganoderma Lucidum on Ulcerative Colitis: A Double-Blind Randomized Controlled Trial

The aim of this study is to determine the efficacy and safety of Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum on ulcerative colitis

Inclusion Criteria:

• age ≥18 years old
• ulcerative colitis patients who are treated by 5-aminosalicylic acid (5-ASA) 3x500 mg
• agreed to participate in this study

Exclusion Criteria:

• ulcerative colitis patients who are treated by corticosteroid, immunosuppressive agents and biologic agents
• allergic to Ganoderma lucidum
• could not be randomised and participate in this study by clinical judgement